Clinical Relevance of Cancerization of Ducts in Resected Pancreatic Ductal Adenocarcinoma.
Journal
Pancreas
ISSN: 1536-4828
Titre abrégé: Pancreas
Pays: United States
ID NLM: 8608542
Informations de publication
Date de publication:
01 Jul 2024
01 Jul 2024
Historique:
medline:
18
6
2024
pubmed:
18
6
2024
entrez:
18
6
2024
Statut:
ppublish
Résumé
Although prevalent in 50%-90% of pancreatic ductal adenocarcinomas, the clinical relevance of "cancerization of ducts" (COD) remains unknown. Pathologists retrospectively reviewed slides classifying prevalence of COD. Histopathological parameters, location of first recurrence, recurrence-free survival (RFS), and overall survival (OS) were collected from the institutional pancreatectomy registry. Among 311 pancreatic ductal adenocarcinomas, COD was present in 216 (69.5%) and more prevalent in the cohort that underwent upfront surgery (75.3% vs 63.1%, P = 0.019). Furthermore, COD was associated with female gender (P = 0.040), advanced T stage (P = 0.007), perineural invasion (P = 0.014), lymphovascular invasion (P = 0.025), and R1 margin (P = 0.009), but not N stage (P = 0.401) or tumor differentiation (P = 0.717). In multivariable regression, COD was associated with less liver recurrence (odds ratio, 0.44; P < 0.005). This association was driven by the cohort of patients who had received preoperative treatment (odds ratio, 0.18; P < 0.001). COD was not predictive for RFS or OS. Cancerization of ducts was not associated with RFS or OS. Currently underrecognized, standardized implementation into histopathological reports may have merit, and further mechanistic scientific experiments need to illuminate its clinical and biologic impact.
Identifiants
pubmed: 38888841
doi: 10.1097/MPA.0000000000002326
pii: 00006676-202407000-00008
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e528-e536Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48.
Groot VP, Rezaee N, Wu W, et al. Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma. Ann Surg. 2018;267:936–945.
Jones RP, Psarelli EE, Jackson R, et al. Patterns of recurrence after resection of pancreatic ductal adenocarcinoma: a secondary analysis of the ESPAC-4 randomized adjuvant chemotherapy trial. JAMA Surg. 2019;154:1038–1048.
Suenaga M, Fujii T, Kanda M, et al. Pattern of first recurrent lesions in pancreatic cancer: hepatic relapse is associated with dismal prognosis and portal vein invasion. Hepatogastroenterology. 2014;61:1756–1761.
Mierke F, Hempel S, Distler M, et al. Impact of portal vein involvement from pancreatic cancer on metastatic pattern after surgical resection. Ann Surg Oncol. 2016;23(Suppl 5):730–736.
Habib JR, Kinny-Köster B, van Oosten F, et al. Periadventitial dissection of the superior mesenteric artery for locally advanced pancreatic cancer: surgical planning with the “halo sign” and “string sign”. Surgery. 2021;169:1026–1031.
Lapshyn H, Bolm L, Kohler I, et al. Histopathological tumor invasion of the mesenterico-portal vein is characterized by aggressive biology and stromal fibroblast activation. HPB (Oxford). 2017;19:67–74.
Hruban RH, Gaida MM, Thompson E, et al. Why is pancreatic cancer so deadly? The pathologist's view. J Pathol. 2019;248:131–141.
Yamasaki S, Suda K, Nobukawa B, et al. Intraductal spread of pancreatic cancer. Clinicopathologic study of 54 pancreatectomized patients. Pancreatology. 2002;2:407–412.
Hutchings D, Waters KM, Weiss MJ, et al. Cancerization of the pancreatic ducts: demonstration of a common and under-recognized process using immunolabeling of paired duct lesions and invasive pancreatic ductal adenocarcinoma for p53 and Smad4 expression. Am J Surg Pathol. 2018;42:1556–1561.
Fujikura K, Hutchings D, Braxton AM, et al. Intraductal pancreatic cancer is less responsive than cancer in the stroma to neoadjuvant chemotherapy. Mod Pathol. 2020;33:2026–2034.
Kerner H, Lichtig C. Lobular cancerization: incidence and differential diagnosis with lobular carcinoma in situ of breast. Histopathology. 1986;10:621–629.
Haffner MC, Weier C, Xu MM, et al. Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization. J Pathol. 2016;238:31–41.
Lee JW, Zhang Y, Yoshizawa T, et al. Cancerization of ducts in hilar cholangiocarcinoma. Virchows Arch. 2022;481:1–10 Published online May 9, 2022.
Basturk O, Hong SM, Wood LD, et al. A revised classification system and recommendations from the Baltimore Consensus Meeting for Neoplastic Precursor Lesions in the Pancreas. Am J Surg Pathol. 2015;39:1730–1741.
Singhi AD, Wood LD. Early detection of pancreatic cancer using DNA-based molecular approaches. Nat Rev Gastroenterol Hepatol. 2021;18:457–468.
Thompson ED, Roberts NJ, Wood LD, et al. The genetics of ductal adenocarcinoma of the pancreas in the year 2020: dramatic progress, but far to go. Mod Pathol. 2020;33:2544–2563.
Connor AA, Gallinger S. Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data. Nat Rev Cancer. 2022;22:131–142.
Herbst B, Zheng L. Precision medicine in pancreatic cancer: treating every patient as an exception. Lancet Gastroenterol Hepatol. 2019;4:805–810.
Kinny-Köster B, Habib JR, Wolfgang CL, et al. Favorable tumor biology in locally advanced pancreatic cancer - beyond CA19-9. J Gastrointest Oncol. 2021;12:2484–2494 Published online 2021.
Oba A, Croce C, Hosokawa P, et al. Prognosis based definition of resectability in pancreatic cancer: a road map to new guidelines. Ann Surg. 2022;275:175–181 Published online March 6, 2020.
Hosoda W, Chianchiano P, Griffin JF, et al. Genetic analyses of isolated high-grade pancreatic intraepithelial neoplasia (HG-PanIN) reveal paucity of alterations in TP53 and Smad4. J Pathol. 2017;242:16–23.
Miyabayashi K, Baker LA, Deschênes A, et al. Intraductal transplantation models of human pancreatic ductal adenocarcinoma reveal progressive transition of molecular subtypes. Cancer Discov. 2020;10:1566–1589.
Makohon-Moore AP, Matsukuma K, Zhang M, et al. Precancerous neoplastic cells can move through the pancreatic ductal system. Nature. 2018;561:201–205.
Connor AA, Denroche RE, Jang GH, et al. Integration of genomic and transcriptional features in pancreatic cancer reveals increased cell cycle progression in metastases. Cancer Cell. 2019;35:267–282.e7.
Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531:47–52.
Sakamoto H, Attiyeh MA, Gerold JM, et al. The evolutionary origins of recurrent pancreatic cancer. Cancer Discov. 2020;10:792–805.
Makohon-Moore AP, Zhang M, Reiter JG, et al. Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer. Nat Genet. 2017;49:358–366.
Paik KY, Choi SH, Heo JS, et al. Analysis of liver metastasis after resection for pancreatic ductal adenocarcinoma. World J Gastrointest Oncol. 2012;4:109–114.
Habib JR, Kinny-Köster B, Bou-Samra P, et al. Surgical decision making in pancreatic ductal adenocarcinoma: modeling prognosis following pancreatectomy in the era of induction and neoadjuvant chemotherapy. Ann Surg. 2023;277:151–158 Published online April 9, 2021.
Honselmann KC, Pergolini I, Castillo CFD, et al. Timing but not patterns of recurrence is different between node-negative and node-positive resected pancreatic cancer. Ann Surg. 2020;272:357–365.
Cai B, Bergmann F, Lu Z, et al. A histopathological study of artery wall involvement in pancreatic cancer surgery. Langenbecks Arch Surg. 2022;407:3501–3511 Published online November 7, 2022.
Groot VP, Gemenetzis G, Blair AB, et al. Implications of the pattern of disease recurrence on survival following pancreatectomy for pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2018;25:2475–2483.